Pharma channel feed – Endpoints News

Pharma channel feed

FDA offers quick thumbs up to expand Dupixent's atopic dermatitis label as Regeneron/Sanofi plot blockbuster moves

7 years ago

EMA launches operations in Amsterdam

7 years ago

AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres

7 years ago

Is second time the charm for ozanimod? Celgene starts to find out with EMA filing

7 years ago

Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs

7 years ago

Roche claims a first in breast cancer as Tecentriq/Abraxane combo nabs quick approval in frontline use

7 years ago

FDA experts gun down a big part of Sanofi's pitch for their controversial vaccine

7 years ago

FDA reverses course, decides not to add suffixes to older biologics’ nonproprietary names

7 years ago

'We can't': Jeff Leiden stands his ground as MPs grill Vertex on pricing disagreement with NHS

7 years ago

Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut

7 years ago

Atul Gawande takes aim at surging prescription drug costs as chief of cryptic Buffett-Bezos-Dimon venture now christened 'Haven'

7 years ago

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

7 years ago

J&J wins FDA OK for their nasal spray version of a party drug, now approved for treatment-resistant major depression

7 years ago

Popular FDA commish Scott Gottlieb has handed in his resignation

7 years ago

The drug pricing debate in America reaches a boiling point at #JPM19

7 years ago

Citing lingering concerns, FDA stops Evoke at the 10-yard line a month before PDUFA date

7 years ago

With $1.4B bet riding on their decision, myelofibrosis drug left for dead by Sanofi hits FDA's inside track to a blockbuster comeback

7 years ago

Senators seek changes to FDA guidance to speed entry of insulin biosimilars

7 years ago

Vertex’s 3-year feud with NICE is about to come to a head as CEO Leiden heads to London

7 years ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers

7 years ago

Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

7 years ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

7 years ago

Gottlieb testifies on status of FDA operations after government shutdown

7 years ago

First page Previous page 274 275 276277278 279 280 Next page Last page